These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 22274144

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N.
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. An update of treatment options for neovascular age-related macular degeneration.
    Iu LP, Kwok AK.
    Hong Kong Med J; 2007 Dec; 13(6):460-70. PubMed ID: 18057435
    [Abstract] [Full Text] [Related]

  • 49. [Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?].
    Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y.
    Harefuah; 2008 Jul; 147(7):605-6, 662. PubMed ID: 18814519
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H, Li X, Xie F.
    Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
    Ng EW, Adamis AP.
    Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
    [Abstract] [Full Text] [Related]

  • 57. Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    O'Shea JG.
    Clin Exp Optom; 2012 Sep; 95(5):541-3. PubMed ID: 22672003
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Intravitreal aflibercept for neovascular age-related macular degeneration.
    Xu D, Kaiser PK.
    Immunotherapy; 2013 Feb; 5(2):121-30. PubMed ID: 23413903
    [Abstract] [Full Text] [Related]

  • 60. New treatments for age-related macular degeneration.
    Avery RL.
    Lancet; 2007 Oct 27; 370(9597):1479-80; author reply 1480. PubMed ID: 17964341
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.